Environmental Amsler test as a monitoring tool for retreatment with ranibizumab for neovascular age-related macular degeneration

Eye

Volumn 26, Issue 3, 2012, Pages 389-393

  Mathew, R ^a   Sivaprasad, S ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

environmental Amsler; neovascular AMD

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; DETERIORATION; DISEASE ACTIVITY; ENVIRONMENTAL AMSLER TEST; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; OPTICAL COHERENCE TOMOGRAPHY; PERCEPTION; PREDICTIVE VALUE; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; SENSITIVITY AND SPECIFICITY; VISUAL ACUITY; VISUAL FIELD; VISUAL IMPAIRMENT;

EID: 84858110200     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2011.326     Document Type: Article

References (11)

1. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-583.
2. Trevino R. Recent progress in macular function self-assessment. Ophthalmic Physiolog Opt 2008; 28: 183-192. (Pubitemid 351569418)
3. Ranibizumab: The clinician's guide to commencing, continuing and discontinuing treatment. http://www.rcophth.ac.uk. RCOphth Scientific Department - June 2008.
4. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR. Improved vision-related function after ranibizumab treatment of neovascular AMD: results of a randomized clinical trial. Arch Ophthalmol 2007; 125(11): 1460-1469. (Pubitemid 350106676)
5. Fletcher DC, Schuchard RA. Visual function in patients with choroidal neovascularization resulting from age-related macular degeneration: the importance of looking beyond visual acuity. Optom Vis Sci 2006; 83: 178-189.
6. Schuchard RA. Validity and interpretation of Amsler grid reports. Arch Ophthalmol 1993; 111(6): 776-780. (Pubitemid 23170589)
7. Fine AM, Elman MJ, Ebert JE, Prestia PA, Starr JS, Fine SL. Earliest symptoms caused by neovascular membranes in the macula. Arch Ophthalmol 1986; 104(4): 513-514. (Pubitemid 16086332)
8. Achard OA, Safran AB, Duret FC, Ragama E. Role of the completion phenomenon in the evaluation of Amsler grid results. Am J Ophthalmol 1995; 120(3): 322-329.
9. Das R, Shi Y, Silvestri G, Chakravarty U. Distortion maps from preferential hyperacuity perimetry are helpful in monitoring functional response to Lucentis therapy. Retina 2009; 29: 1013-1018.
10. Isaac DLC, Avila MP, Cialdini AP. Comparison of the original Amsler grid with the preferential hyperacuity perimeter for detecting choroidal neovascularization in age-related macular degeneration. Arq Bras Oftalmol 2007; 70(5): 771-776.
11. Trevino R, Kynn MG. Macular function surveillance revisited. Optometry 2008; 7: 397-403.